PRMT3 and endometrial cancer: Functionally, PRMT3 inhibition sensitizes endometrial cancer cells to PD-1 blockade, cisplatin, and radiotherapy, highlighting PRMT3 as a novel therapeutic target that indirectly modulates METTL14 activity to enhance ferroptosis and immunotherapy efficacy.